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Differential activation of Fas (CD95) mediated apoptosis by
apple procyanidins in human colon cancer cells SW480 and their
derived metastatic cells SW620
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SUMMARY
Introduction: We investigated the effects of apple procyanidins (Pcy), oligomers of catechins and epicatechins on Fas
receptor expression and function in human colon adenocarcinoma cells (SW480) and in their derived metastatic cells
(SW620).
Methods: Pcy  were characterized by reverse-phase HPLC. Cell death, Fas proteins, DNA fragmentation, and mitochon-
drial membrane potential were analyzed by flow cytometry. Fas mRNA was analyzed by RT-PCR in real time.
Results: Pcy up-regulated the expression of the Fas receptor at the cell surface of both cell lines but activated Fas gene
transcription only in SW620 cells. In SW480 cells, Pcy combined with Fas agonist CH-11 enhanced Fas-mediated apoptosis
involving the loss of mitochondrial membrane potential and DNA fragmentation, which were abrogated by the antagonist
antibody of Fas receptor, the anti-Fas ZB4. On the contrary, in SW620 cells, CH-11 was not able to enhance Pcy-triggered
apoptosis indicating that Fas receptor-mediated apoptosis was not activated in these cells despite an up-regulation of Fas
receptor gene expression. However, it was observed in SW620 cells that Pcy activated the Fas receptor-mediated apoptotic
pathway after a specific blockage of TRAIL-death DR4/DR5 receptors.
Conclusions: The present data showed that Pcy were able to activate the Fas receptor apoptotic pathway in SW480 cells
and favored a cross-talk between TRAIL and Fas receptors in SW620 cells because specific blocking of TRAIL death
receptors favored activation of the Fas receptor-mediated apoptosis. These important data may allow the emergence of new
therapeutic protocols targeting death receptors against resistant metastatic cells.
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Activación diferencial de la apoptosis vía Fas (CD95) por procianidinas de manzana en células humanas de cáncer
de colon y sus derivadas metastásicas
RESUMEN
Introducción: Se estudiaron los efectos de procianidinas (Pcy) de manzana, oligómeros de catequinas y epicatequinas
en la expresión y función del receptor Fas en células humanas de cáncer de colon (SW480) y sus derivadas metastásicas
(SW620).
Métodos: Las Pcy se caracterizaron por cromatografía líquida de alta presión (HPLC) en fase-reversa. Se analizaron por
citometría de flujo la muerte celular, la proteína Fas, la fragmentación del ADN y el potencial de la membrana mitocondrial.
Se analizaron los transcriptos de Fas por RT-PCR en tiempo real.
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Resultados: Las Pcy aumentaron la expresión del recep-
tor Fas en la superficie celular de ambas líneas celulares pero
la transcripción del gen Fas fue activado transcripcionalmente
sólo en las células SW620. En las células SW480, las Pcy
combinadas con el agonista de Fas CH-11 potenció la
apoptosis mediada por Fas involucrando la pérdida del
potencial mitocondrial de membrana y la fragmentación del
ADN los cuales fueron evadidos por el anticuerpo antagonis-
ta del receptor Fas anti-ZB4. Por el contrario, en las células
SW620, CH-11 no fue capaz de potenciar la apoptosis
activada por Pcy indicando que la apoptosis mediada por el
receptor Fas no fue activada en estas células a pesar del
aumento en la expresión de Fas por regulación a nivel
transcripcional. Sin embargo, se observó en las células SW620
que las Pcy activaron la vía apoptótica mediada por el
receptor Fas después de un bloqueo específico de los recep-
tores de muerte TRAIL DR4/DR5.
Conclusiones: Estos datos muestran que las Pcy fueron
capaces de activar la apoptosis a través del receptor Fas en las
células SW480 y favorecieron una intercomunicación entre
los receptores TRAIL y Fas en las células SW620 debido a
que el bloqueo específico de los receptores de muerte TRAIL
favoreció la activación de la apoptosis mediada por el recep-
tor Fas. Estos datos podrían permitir el surgimiento de
nuevos protocolos terapéuticos dirigidos contra receptores
de muerte en células metastásicas resistentes.
Palabras clave: Apoptosis; Cáncer colorectal;
Flavonoides; Procianidinas; Fas; TRAIL.
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Over the past few years, it has been shown that
phytochemicals present in the human diet can prevent
the occurrence of degenerative diseases such as cancer1.
Apples are a rich source of polyphenol constituents,
especially of flavonoids distributed in the peel, core,
and pulp. Flavonoids present in apples are divided into
different classes: flavonols like quercetin conjugates
(3-galactoside, 3-glucoside, and 3-rhamnoside), flavan-
3-ols derivatives including oligomers formed by catechin
and epicatechin units, and the procyanidins (Pcy)2.
Pcy have recently gained interest because of potential
health promoting effects by acting as antioxidant,
anticarcinogen, cardio-preventive, antimicrobial, anti-
viral, and neuro-protective agents2. We have recently
reported that apple Pcy inhibit the growth of human
metastatic colon adenocarcinoma-derived SW620 cells
through the inhibition of protein kinase C activity,
down-regulation of polyamine biosynthesis and
activation of polyamine catabolism, and through Pcy-
triggered apoptosis involving TRAIL receptor-mediated
pathway3-5. It was also reported that apple Pcy can
inhibit the promotion/progression phases of colon
carcinogenesis in rats3. However, the cellular and
molecular mechanisms by which Pcy induce apoptosis
in cancer cells are not well understood. Previously, we
reported that TRAIL-DR4/DR5 blocking antibodies
increased Pcy-triggered apoptosis in SW620 cells4.
These data suggested the activation of an alternative
death pathway. In the present report, we investigated on
the possible implication of the Fas pathway.
Fas (Apo-1/CD95) is a member of the tumour
necrosis factor (TNF) receptor super family activated
by Fas-ligand (FasL) or certain agonist anti-Fas anti-
bodies6 resulting from the activation of an apoptotic
process in sensitive cells. The Fas system is one of the
death-pathways activated in tumour cells by cytotoxic
T lymphocyte cells in the human body. The signals of
Fas ligand (FasL) or agonist antibodies are transduced
by intracellular death domains that interact with adapter
molecules, which are conserved among the TNF recep-
tor super family (TRAIL-DR4/DR5, TNFR1). The
adapter molecule Fas-associated death domain (FADD)
binds directly to the death domains of the TNF receptor
super family to transduce the apoptotic signal leading to
the activation of caspase-8 and, subsequently, to the
downstream activation of effector caspases such as
caspase-3. Activation of the Fas pathway may also
induce a mitochondria-dependent apoptotic pathway
and, depending on the cell type, either one or both
signaling pathways may be activated6.
Most cancer cells, unlike normal cells, are resistant to
Fas-mediated apoptosis, allowing immune escape and
cell growth of a selective population of malignant cells
that may consequently facilitate metastatic spread7,8. The
loss of sensitivity to Fas-mediated apoptosis may play an
important role in the progression of malignancy. This is
supported by the observation that tumour cells dis-
playing resistance to chemotherapeutic agents may conco-
mitantly exhibit resistance to functional Fas expression9.
In the present report, we investigated the effects of apple
Pcy on Fas receptor expression and function in human
colon adenocarcinoma SW480 cells and in their
Fas-resistance derived metastatic SW620 cells.
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MATERIALS AND METHODS
Isolation and characterization of apple pro-
cyanidins. Polyphenols were purified as described in
Maldonado-Celis et al.5 In brief, cider apples (Malus
domestica, Antoinette variety) were reduced into a
homogeneous powder extracted by water:ethanol:acetic
acid (975:1000:25). After filtration, evaporation under
vacuum and freeze drying, the crude extract was
dissolved in 2.5% acetic acid and separated by
preparative HPLC (Lichrospher RP 18, 12 µm, Merck,
Darmstadt, Germany) to remove sugars and other non-
phenolic polar compounds. Polyphenols were eluted
with acetonitrile:water:acetic acid (300:700:25).
Fractions containing polyphenols were evaporated and
freeze-dried. The polyphenols were fractionated on a
Fractogel column by a method adapted from Souquet et
al.10 Pcy were characterized and quantified by thiolysis
coupled with reverse-phase HPLC. On a weight basis,
the Pcy-fraction contained 78% Pcy, consisting of 95%
(-)-epicatechin and 4% (+)-catechin. The mean degree
of polymerization was close to seven. The Pcy fraction
was almost totally devoid of monomeric flavonoids and
other phenols (<2%). Pcy was diluted in dimethyl-
sulfoxide (DMSO) and used at 80 µg/ml final
concentration.
Cell culture and treatments. SW480 and SW620
cells were obtained from the European Collection of
Animal Cell Culture (ECACC, Salisbury, UK). They
were cultured in 75 cm2 Falcon flasks in Dulbecco’s
modified Eagle’s medium containing 25 mM glucose
and 2 mM L-glutamine, 10% heat-inactivated (56°C)
horse serum, 100 U/ml penicillin, 100 µg/ml strepto-
mycin, and 1% non-essential amino acids (Invitrogen
Corp., Cergy Pontoise, France). Incubations were carried
out at 37°C in a humidified atmosphere with 5% CO2.
The culture medium was replaced every 48 h. For all
experiments, horse serum was reduced to 3%, and the
medium was supplemented with 10 mg/ml insulin, 5
mg/ml transferring, and 5 ng/ml selenium and (ITS-
defined medium; Gibco, Invitrogen, Cergy-Pontoise,
France). Cells were exposed to different compounds 24
h after seeding and incubated for 24 or 48 h. DMSO
final concentration in culture medium was 0.1% for
control and treated cells. Stock solution of human Fas-
activating monoclonal antibody (clone CH-11; MBL,
Nagoya, Japan) was tested at 50 ng/ml. The human Fas-
blocking antibody (clone ZB4; MBL, Nagoya, Japan)
was added at 1 mg/ml 1 h before treatment with Pcy. For
experiments with DR4/DR5 blocking antibodies, cells
were pre-treated with human blocking anti-DR4 and
anti-DR5 (250 ng/ml) (Alexis Biochemicals, Switzer-
land) for 24 h before Pcy treatment.
Detection of cell surface expression of Fas recep-
tor (CD95). Cells were treated with Pcy (80 µg/ml) for
48 h and harvested by trypsinization. Cells pellets were
washed with PBS and incubated for 30 min at 4°C in
darkness with FITC-conjugated mouse anti-human-
CD95 (IgG1k, clone DX2, 1:50) (BD Pharmingen, San
José CA, USA) or FITC-conjugated mouse IgG1
monoclonal isotype control antibody (BD Bioscence,
Belgium) for 30 min at 4°C in the dark. After washing
with PBS, cells were re-suspended in PBS, and the
fluorescence of 10,000 events per sample was analyzed
with a FACScan flow cytometer and CellQuest Soft-
ware (BD Biosciences, Belgium).
Total RNA extraction and RT-PCR detection of
Fas (CD95) mRNA transcripts. To know whether cell
surface expression of Fas at the surface level was
associated with levels of Fas RNA, the expression of
Fas mRNA was quantified by real time RT-PCR and
data were analyzed by relative quantification method11.
Relative quantification describes the change in
expression of the target gene (Fas) relative to untreated
cells (control group) under same conditions for detection
of cell surface expression of Fas. Total RNA from
untreated and treated cells with Pcy was extracted by
using an RNeasy mini kit (QIAGEN, VWR, Denmark)
following manufacturer instructions. RNA was reversed
transcribed by using the High-Capacity cDNA Archive
Kit (Applied Biosystems, Foster City CA, USA).
TaqMan Gene Expression assays were used to measure
transcription levels of the selected genes (Fas receptor,
Hs00236330 m1; Applied Biosystems). Beta actin was
applied as an endogenous control (cat no Hs99999903
m1; Applied Biosystems). Real time RT-PCR was
performed by using TaqMan Universal PCR master
mix (Applied Biosystems) and ABI Prism 7500
Sequence Detection System (Applied Biosystems
Sequence detector) in triplicate wells. Data were
analyzed by a comparative threshold cycle (CT) method
and statistical analysis was performed as described by
Livak and Schmittgen11.
Cell death analysis by flow cytometry. We used
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propidium iodide staining to measure the percentage of
cell population in the SubG0/G1 region, which exhibits
DNA content lower than 2 n caused characteristics of
cells dying exhibiting DNA degradation. Thus, this
approach allows determining the amount of dead or
dying cells in a population but gives no information on
the cell death process such as apoptosis12. SW480 and
SW620 cells were seeded in culture dishes and harvested
by trypsinization at 24 and 48 h after treatment with
DMSO 0.1% (control), Pcy (80 µg/ml), anti-Fas agonist
CH-11, and blocking antibodies: anti-Fas ZB4, anti-
DR4, anti-DR5. Cells were centrifuged and fixed in 1
ml methanol:PBS (9:1, v/v) at -20°C for at least 30 min,
washed twice in phosphate buffer saline (PBS) and
resuspended in 200 ml PBS containing 0.25 mg/ml
RNAse A and 0.1 mg/ml propidium iodide (PI) (Sigma-
Aldrich, Munich, Germany), incubated in the dark at
37°C for 30 min. The fluorescence of 10,000 cells was
analyzed by flow cytometry and CellQuest software
(FACScan, BD Biosciences, Erembodegem, Belgium).
Determination of apoptosis by terminal deoxy-
nucleotide transferase (TdT) dUTP-biotin nick-end
labeling (TUNEL) assay13. Cell DNA fragmentation
was achieved via the TUNEL assay; the Mebstain
apoptosis kit (MBL, Nagoya, Japan) was used following
the manufacturer’s instructions. Briefly, cells were
washed with PBS (2% BSA) two times and fixed with
4% paraformaldehyde for 30 min at 4°C. Cells were
permeabilized by adding 200 ml of 0.5% Tween-20
with 0.2% BSA to the cell pellet. The TdT reaction was
carried out in the presence of the FITC-dUTP reagent.
For positive control, H2O2 (1.1%, v/v) was added to the
cell culture medium 30 min before trypsinization. Data
from 10,000 events per sample were collected and
analyzed by using a FACScan flow cytometer
(FACScan, BD Biosciences, Erembodegem, Belgium).
 Mitochondrial membrane permeability changes.
Changes in mitochondrial membrane permeability were
assessed by using the MitoProbe™ DiOC2(3) assay kit
(Invitrogen Corp., France) as described previously5.
Cells were cultured with Pcy and harvested by
trypsinization at 48 h. After trypsinization, cells were
stained with DiOC2(3) or for positive control with a
mitochondrial membrane-potential disrupter, the
carbonyl cyanide 3-chlorophenylhydrazone (CCCP) at
50 µM at 37°C for 30 min in darkness. Cells were
washed and re-suspended in PBS to analyze 10,000
events by flow cytometry with excitation at 488 nm and
green (FL-1: 515 nm) or red (FL-3, (600 nm) emission
filters according to manufacturer’s instructions. This
method allows quantifying cells with depolarized
mitochondrial membrane by flow cytometry analysis
using CellQuest Software (FACScan, BD Biosciences,
Belgium).
Ethics. All the experiments were conducted adhering
to institutional guidelines from the French Ethics
Committee (authorization N°A67-480, French Ministry
of Agriculture).
Statistical analysis. All data were presented as
mean + standard error (SE) from three independent
experiments. Significant differences between control
and treated groups were evaluated by one-way ANOVA
analysis. Student’s t test or Tukey’s multiple comparison
post-test was used to determine statistical differences
between the data at the level of p<0.05. For the
quantitative RT-PCR data, a paired t-test was used to
evaluate differences between treatments at significance
level of p<0.0001. Statistical analyses were performed
by using GraphPad Prism version 4.0, 2003 (GraphPad
Software, San Diego CA, USA).
RESULTS
Effect of Pcy on cell surface and mRNA expression
of Fas receptor in SW480 and SW620 cells. We
measured the effect of Pcy on the cell surface expression
of the Fas receptor by flow cytometry using a specific
anti human-CD95-FITC antibody, by indicating the
percentage of positive cells expressing Fas when
fluorescence shift to the right was indicative of an
increase of cells expressing Fas receptor at their cell
surface (Figure 1A). The mean fluorescence intensity
(MFI) was also determined by flow cytometry (Figure
1B), a numerical data was used as an indicator of
antigen expression level per cell. As shown in Figure
1A and 1B, the Fas receptor was already expressed at
the surface of untreated SW480 cells, and Pcy-treatment
caused a 3-fold increase of Fas receptor expression with
respect to the control group. On the contrary, under
basal conditions, only a very low percent of SW620
cells expressed the Fas receptor at their surface (3%).
After Pcy treatment, a huge increase (>65%) in the
amount of SW620 cells expressing the Fas receptor was
observed, this corresponded to a 13-fold increased
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expression of Fas receptor per cell when compared to
untreated controls (Figure 1B).
In Figure 1C, the histograms represent the fold
increased mRNA expression of Pcy-treated cells over
non-treated cells analyzed by real time RT-PCR. Pcy
treatment of SW620 cells caused a 22-fold (after 24 h)
% Cells expressing Fas receptor
72.7 ± 0.4*81.2 ± 2.7*Pcy






























































Figure 1. Fas expression of Pcy-treated SW480 and SW620 cells. Treatments were performed with Pcy or
DMSO (control) for 48 h. Percentage of cells expressing Fas-receptor (A) and mean fluorescence intensity
(B) were analyzed by flow cytometry after staining with anti-CD95-FITC (open curve) or the respective
isotype control (filled curve). (C) Fas mRNA expression levels were analyzed by RT-PCR, as described in
the Materials and methods. (A), (B), and (C) are representative independent experiments (n = 3) for each
cell line, data are the mean value ± SE. In (A) and (B) comparisons were performed between control and
Pcy-treated cells via one-way ANOVA: *p<0.05; in (C) by paired t-test: p<0.001.
and 35-fold (after 48 h) increase of the Fas receptor
transcripts, as measured by real time RT-PCR when
compared to untreated cells (Figure 1C). In contrast,
Pcy treatment did not change the level of Fas gene
expression in SW480 cells. These data indicate that Pcy
up-regulated the Fas receptor at a transcriptional level
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in SW620 cells; whereas, in the SW480 cell the Pcy
regulated Fas receptor was expressed at a post-
transcriptional level.
Effect of combined treatment with Pcy and agonist
anti-Fas CH-11 on cell death. SW480 cells are known
to be FasL-sensitive, while their derived metastatic
SW620 cells are FasL-resistant7. As shown in Figure
2A, Pcy in combination with the Fas agonist CH-11
increased by two-fold the amount of hypodiploid SW480
cells (Sub G0/G1 region) when compared to cells
treated with Pcy used as a single drug. In contrast, in
SW620 cells, Pcy in combination with CH-11 did not
affect the percentage of dead or dying cells.
We used the TUNEL method to detect the percentage
of SW480 and SW620 cells with single DNA strand
breaks and to confirm the apoptotic effects caused by
single or combined Pcy with CH-11 (Figure 2B). The
strand breaks were detected by flow cytometry with the
TdT-reaction in the presence of dUTP-FITC. As a
positive control, hydrogen peroxide (H2O2) treated
cells were included as described in the Materials and
methods section. Cells with DNA strand breaks were
detected in both cell lines after treatment with single or
combined Pcy with CH-11. The Fas receptor agonist
(CH-11), when used as a single drug, caused DNA
damage in SW480 cells but not in the metastatic SW620
cells.
During Fas-mediated apoptosis, two different
signaling pathways have been identified depending on
cancer cell type7. One of them, is the mitochondrial
pathway induced after binding of FasL to its receptor,
resulting in the cleavage of Bid protein, the loss of
mitochondrial membrane potential (∆Ψm), favoring
the release of cytochrome c and the activation of
caspases-9, and -3. We examined whether Pcy and/or
CH-11 had an effect on mitochondrial membrane using
flow cytometry after staining cells with DiOC2(3),
using CCCP as a positive control as described in the
Materials and methods section. DiOC2(3) accumulates
in the mitochondrial matrix and is released in the
cytosol after membrane depolarization (membrane with
reduced ∆Ψm corresponding to a reduced green
fluorescence)4. As shown in Figure 2C, the percentage
of SW480 cells with depolarized mitochondrial
membrane induced by Pcy single (21%) or CH-11
(21%) was significantly (p<0.05) increased when Pcy
was combined with CH-11 (35%). Conversely, in
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Figure 2. Induction of cell death and ∆Ψm reduction
of Pcy-treated SW480 and SW620 cells. Treatments
were performed with Pcy and/or agonist anti-Fas
CH-11 for 48 h. Percentages of hypodiploid cells
(subG0/G1 region) (A), apoptotic cells (B), and with
reduced ∆Ψm (C) were determined by flow cytometry
using PI, TUNEL and Di0C2(3), respectively, as
described in the Materials and methods. Columns
represent the mean percentage ± SE of cells of at
least three independent experiments. Statistical
differences between groups of treatments were
determined by Tukey’s multiple comparison post-
test. For each cell line, columns not sharing the
same superscript letter differ significantly, p<0.05.
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SW620 cells Pcy induced an increased percentage of
cells with loss of ∆Ψm (46%); however, this effect was
not modified after the combined treatment with CH-11
(43%). Taken together, these results indicate that Pcy
enhanced the response of SW480 cells to Fas-mediated
apoptosis; whereas, in SW620 cells Pcy did not
overcome the cell resistance to CH-11.
Effects of Fas receptor-blocking ZB4 antibody. To
investigate the correlation between Fas receptor
expression and apoptosis, cells were pre-treated with
blocking anti-Fas ZB4 for 1 h before DMSO (control),
Pcy and/or agonist anti-Fas CH-11 treatments for 48 h.
In SW480 cells, the blocking Fas receptor caused a
significant (p < 0.05) reduction in the amount of apoptotic
cells (percentage of hypodiloid cells) after 48 h of
treatment with Pcy (from 14% to 6%) and Pcy/CH-11
(from 28% to 7%). On the contrary, in SW620 cells, the
amount of apoptotic cells was not modified by the
blocking antibody (Figure 3A). These data indicate that
in SW480 cells, Pcy-triggered death may occur via an
activation of the Fas receptor, but this effect was not
observed for SW620 cells.
Activation of Fas apoptotic pathway after blocking
TRAIL death receptors. In SW480 cells, we showed
previously that Pcy-enhanced cell sensitivity to TRAIL-
induced apoptosis was associated to an up-regulated
expression of DR4/DR5 receptors5. These findings led
us to hypothesize that Pcy might simultaneously activate
TRAIL-DR4/DR5 and Fas receptor-mediated apoptosis.
Fas- and TRAIL-death receptors were blocked
simultaneously with specific blocking anti-Fas (ZB-4)
and anti-DR4/-DR5 antibodies before DMSO (con-
trol), Pcy and/or agonist anti-Fas CH-11 treatments for
48 h. As shown in Figure 3B, the specific inactivation
of DR4/DR5 receptors caused a 50% reduction in the
amount of hypodiploid cells, as observed after Pcy
treatment (Figures 2A and 3A). When SW480 cells
were exposed to the combination of blocking antibodies,
a further significant reduction (p<0.01) in the percentage
of apoptotic cells was observed.
In Pcy-treated SW620 cells, we reported previously
that the amount of apoptotic cells was significantly
enhanced after blocking TRAIL-death receptors DR4
and DR55. These receptors, as well as Fas are similar in
that FADD is recruited directly for activation of the
apoptotic cascade9. Thus, these results led us to consider












































































Figure 3. Effect on Pcy-induced cell death after
blocking Fas and TRAIL death receptors of SW480
and SW620 cells. Pre-treatments of cells were
performed with blocking anti-Fas ZB4 (A) or
combined with Anti-DR4/-DR5 (B) followed of Pcy
and/or agonist anti-Fas CH-11 treatments for 48 h to
measure the percentage of hypodiploid cells with PI
by flow cytometry, as described in the Materials and
methods. For each cell line, columns represent
mean ± SE of at least three independent experiments.
Tukey’s multiple comparison post-test was used to
determine statistical differences between groups
of treatments, columns not sharing the same
superscript differ significantly (p<0.05).
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in SW620 cells after the blocking the TRAIL pathway
might involve the activation of the Fas receptor-pathway.
To test this hypothesis, we exposed Pcy-treated SW620
cells to blocking antibodies against Fas (ZB4) and
DR4/DR5. As shown in Figure 3B, ZB4 counteracted
the pro-apototic effects observed after the inactivation
of DR4/DR5 receptors reducing by 80% the amount of
apoptotic cells. These data showed that in SW620 cells,
Pcy was able to activate the Fas-receptor after blocking
TRAIL-death receptors, explaining, therefore, the
enhanced apoptosis observed when SW620 cells were
exposed to the DR4/DR5 blocking antibody.
DISCUSSION
We investigated the involvement of the Fas receptor
pathway in the Pcy-induced apoptotic response of human
colon adenocarcinoma SW480 cells and their derived
metastatic SW620 cells. In the present report, we showed
that these cell lines responded differently to Pcy-induced
apoptosis. Pcy caused a post-transcriptional activation
of Fas receptor-mediated apoptosis in SW480 cells. In
contrast, the metastatic SW620 cells exhibited a Fas-
resistant phenotype, as described previously7,14 that
could not be circumvented by Pcy treatment despite the
up-regulation of the Fas receptor gene expression.
Surprisingly, activation of the Fas receptor-mediated
apoptotic pathway by Pcy was observed in SW620 cells
only after blocking TRAIL-DR4/DR5 receptor
functions. This result suggests that the Fas-resistant
phenotype may be associated to alterations in the
downstream events between DR4/DR5 and Fas
receptors, a subject that deserves further investigation.
We observed that untreated SW480 cells expressed
Fas receptor at a higher level than for SW620 cells in
which the expression of the Fas receptor was only
marginal, agreeing with previous reports8,14. In
metastatic SW620 cells, Pcy caused the up-regulation
of Fas gene transcripts concomitantly with a huge
expression of the receptor at the cell surface. In SW480
cells, Pcy up-regulated Fas receptor expression at a
post-transcriptional level with an increased (>10%)
percentage of cells expressing the receptor at their
surface. This suggests that Pcy may favor the delivery
of the Fas receptor to the cell membrane. The Fas
receptor is a glycoprotein that requires N-glycan post-
transcriptional modifications for efficient expression
at the cell membrane surface and sensitivity to FasL-
signaling, which has been confirmed by inhibiting
glycosyltranferases leading to an intracellular accu-
mulation of Fas receptors16. Thus, it would be of interest
to determine whether Fas glycosilation is involved in
the Pcy up-regulated expression of the Fas-receptor at
the cellular surface.
The apoptotic signaling pathway activated by the
Fas receptor leading ultimately to caspase-3 activation
is mediated through two main pathways: the DISC/
caspase-8, and the mitochondria/cytochrome C/Apaf-
1/caspase-9 pathways. The activation of the effector
caspase-3, results in the extensive degradation of
chromosomal DNA into oligomers of about 180 bp.
Mitochondria play an important role in cell death
signaling18, alterations in mitochondrial structure and
function occuring in early stages of apoptosis. Further
investigations on the Fas receptor function in SW480
and SW620 cells were assessed by combining Pcy with
the agonist anti-Fas CH-11 reproducing activation by
FasL. Under these conditions, enhanced apoptosis of
SW480 cells was observed as evidenced by increased
amount of hypodiploid cells, loss of mitochondrial
membrane potential, and increased DNA fragmentation.
Our data showed that in SW480 cells, the Fas receptor-
mediated apoptotic pathway is activated by Pcy. The
mitochondrial alterations observed in these cells by Pcy
+ CH-11 have also been reported for anti-Fas CH-11 in
other experimental models17; contrary to the use of
multimeric forms of FasL that induce physiologically
relevant apoptotic signaling type I (without mito-
chondria) pathway through the activation of the Fas
receptor18. The activated type II (mitochondrial)
apoptotic pathway by Pcy + CH-11 may occur
simultaneously with an activation of TRAIL-DR4/DR5-
mediated apoptosis5. Simultaneous activation of TRAIL-
death- and Fas-receptor mediated apoptosis in colon
cancer cells may be considered an important strategy
for colon cancer chemoprevention. Indeed, Fas recep-
tor-mediated apoptosis in cancer cells might contribute
to the cytotoxic effect of CD8+ T and natural Killer
(NK) cells infiltrated into the tumor through FasL
secreted from CD8+T and NK cells leading to the
elimination of the cancer cells8. These results raise the
possibility that a combined treatment with Pcy and
cytotoxic drugs up-regulating Fas receptor at the cell
surface might restore colon cancer cell Fas-sensitivity,
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and may be a promising approach against tumor growth.
On the other hand, SW620 cells were resistant to
Fas-receptor mediated apoptosis when treated by Pcy in
presence of Fas receptor agonist (CH-11), which did
not enhance the apoptotic response of Pcy-treated
SW620 cells despite the up-regulated expression of the
Fas receptor. The existence of consensus sequences in
the promoter of the FAS gene for the p5314 and NF-kB19
transcription factors led us to hypothesize that p53 and
NF-kB might be involved in the increased expression of
Fas mRNA transcripts by Pcy in SW620 cells. Further
investigations now in progress are necessary to address
these questions. Although Pcy did not overcome the
Fas-resistance of SW620 cells, Pcy may activate
alternative apoptotic pathways. We have previously
shown that Pcy initiated in SW620 cells a cross-talk
between the TRAIL (extrinsic) apoptotic pathway and
the mitochondrial (intrinsic) apoptotic pathway
involving enhanced expression of TRAIL-DR4/DR5
receptors in SW480 and SW620 cells, and activated the
polyamine catabolism leading to ROS production, which
participated in mitochondria disruption4,5.
In the present study, we observed that the simul-
taneous inactivation of Fas and TRAIL-DR4/-DR5
receptors inhibited Pcy-induced apoptosis in SW620
cells; this suggested that Fas resistance in the presence
of Pcy may occur at two levels:
i. The ratio between DR4/DR5 and Fas receptors in
cell membrane may play a role in determining Fas-
sensitivity. The number of Fas receptors relative to
DR4/DR5 might not be sufficient to induce Fas-
mediated apoptosis, since both types of receptors
interact similarly with the FADD adaptor protein20
after their activation by the combined Pcy /TRAIL
or Pcy/anti-Fas CH-11 treatments;
ii. DR4/DR5 and Fas receptors have different C-termi-
nal tails. The corresponding region for DR4 and
DR5 positively regulates FADD binding, caspase
activation, and apoptosis; whereas, the C-terminal
tail of Fas receptor has the opposite effect and
inhibits binding of FADD to the receptor death
domain. We may hypothesize that the C-terminal
tail of DR4 and DR5 receptors located outside the
death domain could represent additional regulatory
sites for the activation of the Fas receptor to overcome
an inactivation of DR4/DR5 receptors20. However,
at present there is no evidence showing such a direct
interaction between Fas and DR4/DR5 receptors.
In the present report, we demonstrate the ability of
Pcy to activate the Fas receptor-mediated apoptotic
pathway in the SW480 cells modulating at post-
transcriptional level the expression of Fas through a
mechanism yet unknown leading to mitochondrial
perturbation and DNA fragmentation; whereas, TRAIL-
DR4/-DR5 death-receptor-mediated apoptosis was
triggered by Pcy independent of Fas-receptor activation
(Figure 4A). This supports the view that Pcy may help
cancer cells to recover Fas sensitivity during colon
carcinogenesis contributing to the elimination of cancer
cells by FasL liberated from im-mune cells. In contrast,
the inability of Pcy to sensitize SW620 cells to Fas-
mediated apoptosis despite Pcy-triggered up-regulation
of the Fas receptor expression modulated by Pcy from
cell membrane (Figure 4) suggested a loss of function
for the Fas that may play an important role in progression
toward malignancy. Indeed, it was shown that tumour
cells showing resistance to chemotherapeutic agents
may concomitantly exhibit resistance to functional Fas
receptor expression9,10. Our data suggested that in Fas-
resistant SW620 cells, Pcy were able to initiate a cross-
talk between death receptors because specific blocking
of TRAIL death receptors favored activation of the Fas
receptor-mediated apoptosis (Figure 4B). These
important data may allow the emergence of new thera-
peutic protocols targeting death receptors in metastatic
cells. Further investigations have to be extended to
other cancer cells to understand and identify the
mechanisms by which Pcy might be able to increase cell
sensitivity and bypass resistance to Fas-induced
apoptosis.
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Figure 4. Scheme of the Fas-receptor mediated apoptotic pathways activated by Pcy in
SW480 (A) and SW620 (B) cells
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